Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 10/20 | 0.40 |
| ▸ | SYK | P43405 | 7/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.36 |
| ▸ | JAK1 | P23458 | 5/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | BTK | Q06187 | 2/20 | 0.35 |
| ▸ | ITK | Q08881 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12372625 | 0.88 | JAK3 (0.41) | JAK3SYKCYP2C9MAPK1JAK2 | |
| SCHEMBL2354831 | 0.85 | JAK3 (0.38) | JAK3SYKCYP2C9MAPK1JAK2 | |
| SCHEMBL2361899 | 0.84 | JAK3 (0.39) | JAK3SYKCYP2C9MAPK1KCNH2 | |
| SCHEMBL3434618 | 0.79 | PRKD1 (0.42) | JAK3SYKCYP2C9JAK2JAK1 | |
| SCHEMBL2282305 | 0.78 | SYK (0.45) | JAK3SYKCYP2C9MAPK1JAK2 | |
| SCHEMBL3188154 | 0.78 | TP53 (0.38) | JAK3SYKMAPK1JAK2JAK1 | |
| SCHEMBL2282301 | 0.77 | SYK (0.63) | JAK3SYKCYP2C9JAK2JAK1 | |
| SCHEMBL2273798 | 0.77 | JAK3 (0.59) | JAK3SYKCYP2C9MAPK1CYP2D6 | |
| SCHEMBL1899236 | 0.75 | CNR2 (0.35) | JAK3SYKCYP2C9MAPK1JAK2 | |
| SCHEMBL2357413 | 0.75 | DGAT1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245033-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2011-08-31 | — | — | EP | disclosed |
| US-8008298-B2 | Pyrrolopyrazine kinase inhibitors | Roche Palo Alto (US) | 2011-08-30 | — | — | US | disclosed |
| EP-2245033-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | ROCHE PALO ALTO LLC | 2010-10-21 | — | — | US | disclosed |
| WO-2009106441-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267666-A1 | Pyrrolopyrazine kinase inhibitors | SYK, ZAP70, TYK2 | JAK3 7/4885SYK 1/4885CYP2C9 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.